Nuvalent, Inc. announced the pricing of an underwritten public offering of shares of Class A common stock at $101.00 per share.
The offering consists of 4,950,496 shares, aiming to raise approximately $500.0 million in gross proceeds.
The offering is expected to close on November 20, 2025, subject to customary closing conditions.
Company Focus
Nuvalent is a clinical-stage biopharmaceutical company creating precisely targeted therapies for cancer.
Offering Details
The public offering is priced at $101.00 per share, aiming to raise approximately $500.0 million.
Underwriters
J.P. Morgan, Jefferies, TD Cowen, and Cantor are acting as joint book-running managers for the offering.
- Nuvalent is leveraging its expertise in chemistry and drug design to develop innovative small molecules for cancer treatments.
- The offering, made through an automatically effective shelf registration statement, demonstrates Nuvalent's commitment to advancing its pipeline.
The successful pricing of the public offering reflects investor confidence in Nuvalent's innovative approach to cancer therapies.